Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation

• Status: Unknown status
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, PVI plus linear lesions (LL) plus botulinum toxin injection versus PVI plus linear lesions (LL), in patients with persistent or longstanding persistent AF. Results were assessed with the use of an implanted monitoring device (IMD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Meshalkin Research Institute of Pathology of Circulation
• Treatments: Botulinum Toxins

Criteria

Inclusion Criteria:

• Persistent and longstanding persistent AF

Exclusion Criteria:

• congestive heart failure

• LV ejection fraction < 35%

• left atrial diameter > 60 mm